Enhancing the dissolution of phenylbutazone using Syloid® based mesoporous silicas for oral equine applications

Three mesoporous silica excipients (Syloid® silicas AL-1 FP, XDP 3050 and XDP 3150) were formulated with a model drug known for its poor aqueous solubility, namely phenylbutazone, in an attempt to enhance the extent and rate of drug dissolution. Although other forms of mesoporous silica have been in...

Descripción completa

Detalles Bibliográficos
Autores principales: Waters, Laura J., Hanrahan, John P., Tobin, Joseph M., Finch, Catherine V., Parkes, Gareth M.B., Ahmad, Shamsuddeen A., Mohammad, Faraj, Saleem, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Xi'an Jiaotong University 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004617/
https://www.ncbi.nlm.nih.gov/pubmed/29922487
http://dx.doi.org/10.1016/j.jpha.2018.01.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004617/
https://www.ncbi.nlm.nih.gov/pubmed/29922487
http://dx.doi.org/10.1016/j.jpha.2018.01.004

Ejemplares similares